Al2O3-MgO Hybrid Nanoparticles as an Effective Nanocarrier for Lenalidomide as Anti-Cancer Drug for Treatment of Multiple Myeloma, Smoldering Myeloma, and Myelodysplastic Syndromes
نویسندگان
1 Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan
2 Samarkand State University named after Sharof Rashidov, Uzbekistan
3 Samarkand State University named after Sharof Rashidov, Uzbekistan
4 Bukhara State Pedagogical Institute, Bukhara, Uzbekistan
5 Urgench State Pedagogical Institute, Urgench, Uzbekistan
6 Bukhara State University, Bukhara , Uzbekistan
7 Urgench State University, Urgench, Uzbekistan
8 Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan
9 Tashkent State Medical University, Tashkent, Uzbekistan
10 Jizzakh branch of the National University of Uzbekistan, Jizzakh, Uzbekistan
11 Mamun University, Khorezm, Uzbekistan
12 Asia International University, Bukhara, Uzbekistan
13 National Pedagogical University of Uzbekistan, Tashkent, Uzbekistan
14 Tashkent State University of Economics, Tashkent, Uzbekistan
doi
10.22052/JNS.2025.04.063چکیده
In this study, Al2O3–MgO hybrids were synthesized via aqueous, surfactant-free processing, yielding ≈84% isolated solid and a surface zeta potential of +32 ± 2 mV. LEN was loaded by a 24 h incubation (1:5 drug: carrier w/w) in pH 6.5 buffer, achieving loading capacity (LC) 12.4 ± 0.3% and encapsulation efficiency (EE) 93.1 ± 1.1%. Loading and purity were quantified by HPLC (302 nm; tR 6.8 min) with daily calibration (0.5–50 μg mL−1, R2 ≥ 0.9999). In vitro release used a dialysis-bag method under sink conditions at pH 7.4 and 5.0 (37 °C); cumulative release was UV-Vis monitored (302 nm) and corrected for dilution, revealing near-zero-order kinetics at pH 7.4 and accelerated release at pH 5.0. LEN-loaded Al2O3–MgO demonstrated a 4–6-fold potency advantage over free LEN across MM and MDS cell lines, with negligible toxicity from empty carriers. Confocal imaging showed lysosomal trafficking as the predominant uptake route, aligning with the observed pH-responsive release profile. The system maintains carrier integrity after release and demonstrates high drug-loading efficiency with sustained release, supporting improved therapeutic indices.
